— Know what they know.
Not Investment Advice

SPRY NASDAQ

ARS Pharmaceuticals, Inc.
1W: -16.1% 1M: -21.3% 3M: -50.4% YTD: -58.6% 1Y: -54.7% 3Y: -35.5% 5Y: -79.1%
$4.76
-0.30 (-5.93%)
 
Weekly Expected Move ±11.7%
$4 $4 $5 $5 $6
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 25 · $472.7M mcap · 64M float · 2.99% daily turnover · Short 63% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$472.7M
52W Range4.73-13.15
Volume2,570,805
Avg Volume1,926,206
Beta0.88
Dividend
Analyst Ratings
4 Buy 6 Hold 0 Sell
Consensus Hold
Company Info
CEODonn Casale
Employees195
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-04
11682 El Camino Real
San Diego, CA 92130
US
858 335 1300
About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Recent Insider Trades

NameTypeSharesPriceDate
Smith Margaret Ekins A-Award 1,001,738 $5.77 2026-09-01
Smith Margaret Ekins 0 2026-08-17
Casale Donn A-Award 898,456 $7.96 2026-07-01
Shah Pratik A-Award 30,000 $10.54 2026-06-24
Kelly Michael A-Award 30,000 $10.54 2026-06-24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms